loading page

Polypharmacy among Older Advanced Lung Cancer Patients taking EGFR Tyrosine Kinase Inhibitors
  • +2
  • Taiki Hakozaki,
  • Takuma Matsuo,
  • Akihiro Shimizu,
  • Yoko Ishihara,
  • Yukio Hosomi
Taiki Hakozaki
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Author Profile
Takuma Matsuo
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Author Profile
Akihiro Shimizu
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Author Profile
Yoko Ishihara
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Author Profile
Yukio Hosomi
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Author Profile

Abstract

Aim: Polypharmacy (PP) is a common problem among the older adults and has a potential effect on health-related problems. However, the significance of PP in older advanced non–small cell lung cancer (NSCLC) patients and those on oral molecular-targeted anticancer agents is unclear. Methods: This retrospective study reviewed the records of 334 advanced NSCLC patients who underwent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. PP was defined as >=5 concomitant medications. Potentially inappropriate medication (PIM) use was measured using the updated screening tool of older people’s prescriptions (STOPP) ver. 2 criteria. We also estimated survival distributions using the Kaplan–Meier method, compared between–group differences using the log-rank test, explored potential predictors of survival using Cox regression, and performed cluster analysis to identify factors affecting multiple-medication use. Results: The PP and PIM use prevalence was 38.4% and 31.9%, respectively. The median overall survival (OS) for PP(+) and PP(–) patients was 19.4 months (95% CI = 14.1–24.8) and 27.3 months (95% CI = 22.6–36.4), respectively (P < 0.001). Multivariate analysis revealed a significant correlation between PP and OS. The frequency of unexpected hospitalization during EGFR-TKI treatment was higher in PP(+) compared to PP(–) patients (49.4% vs. 29.4%; P = 0.0032; OR = 2.34; 95% CI = 1.31–4.23). Conclusion: PP is an independent prognostic factor in older NSCLC patients taking EGFR-TKIs. PP can be used as a simple indicator of such patients’ comorbidities and symptoms or as a predictive marker of unexpected hospitalization during treatment.